Examkin

Tüm alıştırma soruları

4736 soru

Tüm türler4,736Çoktan seçmeli2,413Çoklu seçim567Sayısal127Eşleştirme858Sıralama771
Soru 61Soru →

A 65-year-old man presents to a primary care clinic with a 4-day history of worsening cough productive of yellow sputum, subjective fevers, and fatigue. He has a past medical history of hypertension, type 2 diabetes mellitus, and hyperlipidemia. His daily medications include lisinopril, metformin, simvastatin, and low-dose aspirin. Vital signs show a temperature of 38.2°C (100.8°F), blood pressure of 134/82 mmHg, heart rate of 92/min, and respiratory rate of 18/min. Pulse oximetry is 96% on room air. Physical examination reveals crackles in the right lower lung base. A chest radiograph demonstrates a right lower lobe infiltrate. The physician diagnoses community-acquired pneumonia. Given the patient's comorbidities, he is prescribed an outpatient oral regimen of amoxicillin-clavulanate and clarithromycin. Which of the following is the most appropriate modification to this patient's chronic medication regimen during his antibiotic therapy?

Cevabı ve açıklamayı göster

Cevap: Temporarily withhold simvastatin for the duration of the antibiotic course

Cevap

Temporarily withhold simvastatin for the duration of the antibiotic course.
The correct action is to temporarily withhold simvastatin for the duration of the antibiotic course. Clarithromycin is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme, which is responsible for the hepatic metabolism of simvastatin. Coadministration of these two drugs significantly elevates simvastatin serum concentrations, markedly increasing the risk of severe statin-induced myopathy and life-threatening rhabdomyolysis. Because of this well-established and predictable interaction, the concurrent use of simvastatin (or lovastatin) and clarithromycin is absolutely contraindicated by the FDA. The safest and most practical management strategy for a patient requiring a short course of a strong CYP3A4 inhibitor is to simply pause the statin therapy until the antibiotic course is completed, as a brief interruption in lipid-lowering therapy poses no acute cardiovascular risk.

Adım Adım Çözüm

1
Analyze the prescribed antibiotic regimen for potential drug-drug interactions.
Clarithromycin is identified as a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme.
Macrolides (excluding azithromycin) are notorious for causing significant pharmacokinetic interactions by inhibiting hepatic enzymes.
2
Evaluate the patient's chronic medications to identify CYP3A4 substrates.
Simvastatin is identified as a major substrate of CYP3A4.
Inhibition of CYP3A4 drastically decreases the clearance of simvastatin, leading to toxic serum concentrations.
3
Determine the appropriate clinical intervention to mitigate the identified interaction.
The concurrent use of clarithromycin and simvastatin is absolutely contraindicated; the statin must be withheld.
To prevent severe adverse effects such as myopathy and rhabdomyolysis, the offending medication (simvastatin) should be paused during the short course of the antibiotic.

Anahtar Kavram

Management of pharmacokinetic interactions between strong CYP3A4 inhibitors (clarithromycin) and CYP3A4 substrates (simvastatin).
Tahmini Süre:1m 0s
Soru 62Soru →

A 68-year-old man with symptomatic, recurrent atrial fibrillation has failed rate control strategies and is planned for rhythm control with amiodarone. He has a history of coronary artery disease and heart failure with a left ventricular ejection fraction of 35%. You are planning his medication initiation and long-term follow-up. Arrange the following steps regarding the monitoring and treatment evaluation of this patient's amiodarone therapy in the correct chronological order, from baseline preparation to long-term surveillance.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct chronological sequence is: 1) Baseline organ function testing, 2) Acute ECG monitoring during loading, 3) 6-month thyroid and liver function surveillance, and 4) Annual pulmonary and ophthalmic screening.
Amiodarone is a highly effective antiarrhythmic, but it carries a massive burden of potential systemic toxicities due to its lipophilicity, high iodine content, and extremely long half-life. Safe management requires a strict temporal protocol: establishing baseline pulmonary, hepatic, and thyroid function; securing the acute loading phase against proarrhythmias; conducting 6-month interval checks for thyroid and hepatic dysfunction; and maintaining annual checks for chronic pulmonary or ocular damage.

Adım Adım Çözüm

1
Establish baseline clinical parameters prior to drug exposure.
Liver function tests, thyroid function tests, chest radiograph, and pulmonary function tests (including DLCO) are obtained.
Amiodarone causes multi-organ toxicity. Baseline values are essential to differentiate drug-induced injury from pre-existing disease progression.
2
Observe for acute electrical complications during the initial drug loading.
The patient is placed on continuous inpatient telemetry.
The loading phase carries the highest acute risk for severe bradycardia, AV block, and QT prolongation leading to Torsades de Pointes.
3
Implement mid-term surveillance for endocrine and hepatic side effects.
TSH and transaminases are drawn at 6 months.
Due to its high iodine content and lipophilicity, amiodarone can induce thyrotoxicosis, hypothyroidism, and hepatotoxicity, typically becoming apparent within the first 6 to 12 months.
4
Maintain long-term screening for chronic structural toxicities.
Annual chest radiograph and slit-lamp eye exam are scheduled.
Amiodarone pulmonary toxicity (APT) and ocular complications (corneal microdeposits, optic neuropathy) can present insidiously after years of therapy.

Anahtar Kavram

Standardized monitoring protocol for amiodarone toxicity
Soru 63Soru →

A 28-year-old woman presents to the ambulatory care clinic with a 3-day history of painful urination and increased urinary frequency. She reports a sensation of incomplete bladder emptying and mild suprapubic discomfort. She denies fever, chills, flank pain, nausea, vomiting, hematuria, or vaginal discharge. Her last menstrual period was 2 weeks ago. She has no significant past medical history and takes no medications other than an oral contraceptive. Vital signs show a temperature of 37.1°C (98.8°F), blood pressure of 118/76 mm Hg, and heart rate of 78/min. Physical examination reveals mild suprapubic tenderness to palpation but no costovertebral angle tenderness. A urine dipstick in the clinic is positive for leukocyte esterase and nitrites. In the context of providing cost-conscious, high-value care, which of the following is the most appropriate next step in management?

Cevabı ve açıklamayı göster

Cevap: Prescribe a 3-day course of oral trimethoprim-sulfamethoxazole

Cevap

Prescribe a 3-day course of oral trimethoprim-sulfamethoxazole.
The correct answer is to prescribe a 3-day course of oral trimethoprim-sulfamethoxazole. This patient presents with classic signs and symptoms of acute uncomplicated cystitis. According to high-value care principles and current clinical guidelines, uncomplicated cystitis in young, healthy, non-pregnant women should be diagnosed clinically with a confirmatory urine dipstick. Empiric treatment with a first-line antibiotic is the most cost-effective and appropriate management step. This approach avoids unnecessary healthcare expenditures associated with laboratory testing and imaging, limits the use of broad-spectrum antibiotics, and provides definitive, rapid relief for the patient.

Adım Adım Çözüm

1
Analyze the patient's clinical presentation and vital signs.
The patient exhibits classic symptoms of uncomplicated cystitis (dysuria, frequency, suprapubic pain) and has a positive urine dipstick, without red flag symptoms such as fever or flank pain.
To differentiate between simple, uncomplicated lower urinary tract infections and complicated upper urinary tract infections that require more extensive workup.
2
Determine the necessity of further diagnostic testing.
No additional testing, such as urine cultures or imaging, is required.
High-value care guidelines state that clinical symptoms combined with a supportive urine dipstick are sufficient to diagnose uncomplicated cystitis, minimizing unnecessary healthcare expenditures.
3
Select the most guideline-concordant, cost-effective therapeutic intervention.
Empiric treatment with a first-line agent, such as a short course of trimethoprim-sulfamethoxazole, is selected.
This approach provides rapid symptom resolution while supporting antimicrobial stewardship and reducing overall resource utilization.

Anahtar Kavram

High-value care for acute uncomplicated cystitis involves empiric treatment with narrow-spectrum, first-line antibiotics (e.g., trimethoprim-sulfamethoxazole or nitrofurantoin) without the routine use of urine cultures, advanced imaging, or hospital admission.
Tahmini Süre:1m 15s
Soru 64Soru →

A 72-year-old man with chronic kidney disease (baseline creatinine 2.4 mg/dL) and atrial fibrillation is admitted to the general medical floor for community-acquired pneumonia. The resident physician uses the electronic health record (EHR) to prescribe medications. While entering an order for apixaban, the resident receives three consecutive pop-up alerts regarding minor drug interactions with the patient's home supplements and overrides all of them rapidly. A fourth alert warning about the need for renal dose adjustment of apixaban is also inadvertently dismissed. The hospital's EHR does not require a specific justification to override renal dose alerts, and new anticoagulant orders do not require pharmacist verification before dispensing. The patient receives the unadjusted dose of apixaban and two days later experiences a severe gastrointestinal hemorrhage requiring transfer to the intensive care unit. Which of the following represent latent system vulnerabilities that contributed to this adverse event? (Select all that apply.)

Geçerli olan tümünü seçin

Cevabı ve açıklamayı göster

Cevap: Excessive non-critical pop-up notifications in the electronic prescribing system; Absence of a mandatory hard-stop mechanism for high-risk medication alerts; Lack of required clinical pharmacist review for new inpatient anticoagulant orders

Cevap

The latent system vulnerabilities are the excessive non-critical pop-up notifications, the absence of a mandatory hard-stop mechanism, and the lack of required clinical pharmacist review.
Latent errors (blunt-end errors) are inherent vulnerabilities in the design of healthcare systems, processes, or environments that create conditions allowing active errors to occur. In this scenario, three latent vulnerabilities are present. First, the EHR design generates excessive non-critical alerts, causing 'alert fatigue' and making providers desensitized to important warnings. Second, the system lacks a forcing function (hard stop) that would require a specific clinical justification to override a high-risk medication alert. Third, the institutional policy lacks a requirement for pharmacist verification of new anticoagulant orders, removing a crucial independent double-check. These systemic flaws paved the way for the resident's active error to reach the patient and cause harm.

Adım Adım Çözüm

1
Differentiate between active errors and latent system vulnerabilities.
Active errors occur at the 'sharp end' (frontline providers), while latent errors occur at the 'blunt end' (system design, policies, equipment).
The question specifically asks for latent vulnerabilities, so identifying the underlying systemic flaws is required.
2
Analyze the clinical scenario for systemic design flaws.
The EHR generating irrelevant alerts (alert fatigue), the lack of hard stops for critical alerts, and the absence of pharmacist verification are identified as systemic design flaws.
These factors created the unsafe environment that allowed the resident's active error to reach the patient.
3
Analyze the remaining options for active errors.
The resident clicking through the alert and the omission of information during handoff are frontline actions, classifying them as active errors.
Eliminating the active errors isolates the correct latent vulnerabilities.

Anahtar Kavram

Latent system vulnerabilities are underlying organizational, environmental, or system design flaws (blunt-end errors) that create conditions allowing active errors (sharp-end errors) to occur.
Soru 65Soru →

An 82-year-old man with end-stage congestive heart failure (left ventricular ejection fraction of 15%) and severe chronic kidney disease (estimated glomerular filtration rate of 18 mL/min/1.73 m²) is admitted to the hospital with worsening dyspnea and generalized anasarca. This is his fourth admission in the past two months. He is functionally dependent and spends most of his day resting in a chair. Despite aggressive intravenous diuresis over the past 48 hours, he remains highly symptomatic with dyspnea at rest.

During morning rounds, the patient tells the attending physician, "I am so tired of fighting this. I don't want any more blood draws, machines, or hospitals. I just want to go home and be kept comfortable for whatever time I have left."

The physician evaluates the patient and determines that he is fully alert, oriented to person, place, and time, and demonstrates a clear understanding of his diagnosis, prognosis, and the fatal consequences of stopping aggressive medical therapy.

Later that afternoon, the patient's daughter, who is his legally designated healthcare proxy, arrives at the hospital. She is extremely distraught and insists, "You must do everything possible! Put him on dialysis and a breathing machine if you have to. I am his healthcare proxy, and I say he stays here for treatment."

Which of the following is the most appropriate next step in the management of this patient?

Cevabı ve açıklamayı göster

Cevap: Initiate a referral for home hospice care and prescribe low-dose oral morphine to manage his dyspnea.

Cevap

Initiate a referral for home hospice care and prescribe low-dose oral morphine to manage his dyspnea.
The correct response correctly synthesizes ethical principles and palliative symptom management. Because the patient demonstrates clinical capacity (understanding his diagnosis, prognosis, and the consequences of his choices), his autonomous decision to pursue comfort care supersedes the demands of his daughter. Her status as a healthcare proxy is only activated if he loses capacity. Transitioning him to home hospice honors his wishes. Furthermore, prescribing low-dose oral morphine is the medically appropriate treatment for dyspnea (air hunger) in end-stage heart failure, as it decreases the central respiratory drive and reduces the sensation of breathlessness safely and rapidly.

Adım Adım Çözüm

1
Assess the patient's decision-making capacity regarding his goals of care.
The physician determined the patient is alert, oriented, and understands his prognosis and the consequences of his choice. Therefore, he has full clinical decision-making capacity.
Capacity is the foundation of medical ethics; a capable patient's choices dictate the plan of care.
2
Evaluate the authority of the healthcare proxy in this specific scenario.
The daughter's demands are overridden by the patient's autonomous request.
A healthcare proxy (surrogate) only has decision-making authority when the primary patient lacks clinical capacity. Since he has capacity, her legal status as proxy is currently inactive.
3
Determine the appropriate clinical disposition based on the patient's goals.
A referral for home hospice is indicated.
The patient explicitly requested to stop machines/hospitals and focus on comfort at home, which perfectly aligns with hospice care.
4
Select the appropriate pharmacologic management for his acute dyspnea (air hunger).
Prescribe low-dose, short-acting oral morphine.
Short-acting opioids (like oral morphine) are the standard of care for relieving dyspnea in end-stage cardiopulmonary disease. Long-acting or delayed-onset opioids (like fentanyl patches) are contraindicated for acute symptoms in opioid-naive patients.

Anahtar Kavram

In patients with clinical capacity, their autonomous healthcare decisions supersede those of a designated healthcare proxy; home hospice with short-acting opioids is the standard of care for capable patients choosing comfort over life-prolonging measures.
Tahmini Süre:1m 30s
Soru 66Soru →

During a routine health maintenance visit, a 32-year-old female requests advice on her long-term cancer screening needs. She feels entirely well and has no acute concerns. Her past medical history is notable for classic Hodgkin lymphoma, which was diagnosed when she was a 21-year-old college student. At that time, her treatment consisted of 6 cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) alongside involved-field radiation therapy to her neck and mediastinum. She achieved complete remission and has had no disease recurrence in the 11 years since.

Her family history is unremarkable for malignancies. She does not use tobacco, consumes alcohol in moderation, and exercises regularly. Vital signs are within normal limits. A thorough physical examination, including clinical breast and thyroid palpation, reveals no masses or adenopathy. Review of her records indicates a normal Pap smear and negative high-risk human papillomavirus testing performed 2 years ago.

Which of the following is the most appropriate next step in preventive care for this patient?

Cevabı ve açıklamayı göster

Cevap: Annual screening mammography and breast magnetic resonance imaging

Cevap

The most appropriate step is annual screening mammography and breast magnetic resonance imaging.
The correct answer is annual screening mammography and breast magnetic resonance imaging (MRI). Patients who received ≥10\ge 10 Gy of thoracic radiation between the ages of 1010 and 3030 years (e.g., as part of mantle field radiation for Hodgkin lymphoma) have a significantly elevated lifetime risk of developing secondary breast cancer. This risk approaches that seen in patients with BRCA genetic mutations. Consequently, major oncology and radiology guidelines recommend high-risk screening for this population. This regimen consists of annual screening mammography and annual breast MRI beginning 88 years after the completion of radiation therapy, but not before age 2525. Since this patient was treated 1111 years ago at age 2121, she meets all criteria and should begin this intensive screening regimen immediately.

Adım Adım Çözüm

1
Identify the patient's major risk factor for secondary malignancies.
The patient received involved-field radiation therapy to the neck and mediastinum at age 21.
Prior medical treatments, especially radiation and certain chemotherapies during adolescence or young adulthood, significantly alter future cancer screening requirements.
2
Determine the appropriate breast cancer screening protocol based on this risk factor.
Guidelines recommend annual mammography and breast MRI starting 8 years after radiation or at age 25 (whichever is later) for women who received thoracic radiation between ages 10 and 30.
Thoracic radiation in this age window drastically increases the lifetime risk of breast cancer due to the direct exposure of developing breast tissue.
3
Evaluate the patient's current age and time since treatment to select the immediate next step.
The patient is 32 years old and it has been 11 years since her radiation therapy. Therefore, she is immediately due for annual mammography and breast MRI.
She meets both the age (≥25\ge 25 years) and time interval (≥8\ge 8 years) criteria to begin high-risk screening.

Anahtar Kavram

High-risk breast cancer screening after thoracic radiation
Tahmini Süre:1m 15s
Soru 67Soru →

A 72-year-old woman is evaluated in the ambulatory care clinic for a routine follow-up. She has a history of type 2 diabetes mellitus, osteoarthritis, hypertension, and recurrent uncomplicated urinary tract infections. Her current medications include metformin 1000 mg twice daily, sitagliptin 100 mg daily, meloxicam 15 mg daily, nitrofurantoin 100 mg daily, and amlodipine 10 mg daily. The patient reports feeling well overall, though she mentions mild fatigue over the past few weeks. Blood pressure is 132/82 mmHg, and pulse is 76/min. Physical examination is unremarkable, with no peripheral edema.

Laboratory results from today are compared to those from six months ago:

Laboratory TestCurrentSix Months Ago
Blood urea nitrogen42 mg/dL18 mg/dL
Serum creatinine2.6 mg/dL1.1 mg/dL
eGFR19 mL/min/1.73 m²55 mL/min/1.73 m²
Serum potassium4.8 mEq/L4.2 mEq/L

Based on the patient's current laboratory results, which of the following medications must be entirely DISCONTINUED? (Select all that apply)

Geçerli olan tümünü seçin

Cevabı ve açıklamayı göster

Cevap: Metformin; Meloxicam; Nitrofurantoin

Cevap

Metformin, Meloxicam, and Nitrofurantoin must be discontinued.
This patient has developed severe renal impairment (eGFR < 30 mL/min/1.73 m²). In this setting, metformin must be discontinued due to a significantly elevated risk of life-threatening lactic acidosis. Meloxicam, an NSAID, must be stopped because it inhibits prostaglandins that are actively dilating the afferent arteriole to maintain glomerular filtration, further worsening renal function. Nitrofurantoin must also be discontinued because it is essentially cleared by glomerular filtration; at an eGFR < 30 mL/min/1.73 m², it fails to reach therapeutic levels in the urinary tract to prevent UTIs and instead accumulates systemically, leading to pulmonary toxicity and peripheral neuropathy.

Adım Adım Çözüm

1
Analyze the patient's updated laboratory findings.
The patient's eGFR has rapidly declined from 55 to 19 mL/min/1.73 m², indicating new-onset Stage 4 chronic kidney disease (CKD) or acute-on-chronic kidney injury.
Renal function directly determines the safety, efficacy, and necessary dosing adjustments for many pharmacologic agents.
2
Evaluate the current medication list against the new eGFR of 19 mL/min/1.73 m².
Identify which medications are absolutely contraindicated, which need dose adjustments, and which are safe to continue.
Continuing contraindicated medications in advanced CKD can lead to severe systemic toxicity or worsen renal failure.
3
Select the medications that require complete discontinuation.
Metformin (lactic acidosis risk), meloxicam (worsens renal perfusion), and nitrofurantoin (lack of efficacy and high toxicity risk) must be stopped. Sitagliptin only requires a dose reduction, and amlodipine requires no changes.
Differentiating between drugs requiring dose adjustments and those requiring absolute discontinuation is critical for safe medication reconciliation.

Anahtar Kavram

Medication reconciliation and identification of absolute pharmacologic contraindications in the setting of severely impaired renal function (eGFR < 30 mL/min/1.73 m²).
Soru 68Soru →

A 34-year-old woman with Hashimoto thyroiditis comes to the clinic for a routine follow-up evaluation. She has been stable on a daily levothyroxine dose of 112 mcg112 \text{ mcg} for the past 2 years. Eight weeks ago, she was prescribed an oral estrogen-progestin contraceptive for menorrhagia. The patient currently feels well and reports no fatigue, weight changes, constipation, or cold intolerance. Her vital signs are within normal limits. Physical examination reveals a normal, nonpalpable thyroid gland and no peripheral edema. Which of the following is the most appropriate next step in the management of this patient?

Cevabı ve açıklamayı göster

Cevap: Measure serum thyroid-stimulating hormone concentration

Cevap

Measure serum thyroid-stimulating hormone concentration
The most appropriate next step in management is to measure the serum thyroid-stimulating hormone (TSH) concentration. Oral estrogens undergo significant first-pass hepatic metabolism, which stimulates the liver to synthesize increased amounts of thyroxine-binding globulin (TBG). In a healthy individual, the resulting transient decrease in free T4 stimulates the pituitary gland to secrete more TSH, prompting the normal thyroid gland to produce more thyroid hormone and maintain a euthyroid state. However, patients with primary hypothyroidism lack this compensatory capacity. As a result, the increased TBG binds the exogenous levothyroxine, leading to a sustained decrease in free T4 and potentially causing clinical or subclinical hypothyroidism. Therefore, patients on levothyroxine who initiate oral estrogen therapy must have their TSH levels monitored 6 to 8 weeks after starting the medication to determine if an increase in the levothyroxine dosage is necessary. Even if the patient is currently asymptomatic, proactive testing is required as biochemical changes precede clinical symptoms.

Adım Adım Çözüm

1
Identify the patient's underlying condition and recent medication changes.
The patient has primary hypothyroidism, is on a stable dose of levothyroxine, and recently started an oral estrogen-progestin contraceptive.
Establishing the temporal relationship between baseline therapies and newly added medications is necessary to identify potential drug interactions.
2
Analyze the pharmacokinetic effect of the new medication.
Oral estrogens undergo first-pass hepatic metabolism and stimulate the liver to synthesize increased amounts of thyroxine-binding globulin (TBG).
Understanding how oral estrogens alter serum transport proteins is required to predict changes in active hormone levels.
3
Determine the clinical consequence of this physiologic change.
Increased TBG binds more circulating T4, decreasing the biologically active free T4 fraction. Because the patient lacks endogenous thyroid function, she cannot compensate by producing more T4, placing her at risk for iatrogenic hypothyroidism.
This establishes the risk of clinical deterioration despite the patient currently being asymptomatic.
4
Select the appropriate monitoring strategy.
Measure the serum TSH level 6 to 8 weeks after the initiation of estrogen therapy to determine if a levothyroxine dose adjustment is required.
TSH is the most sensitive and accurate marker for assessing the adequacy of thyroid hormone replacement in primary hypothyroidism.

Anahtar Kavram

Monitoring levothyroxine therapy following the initiation of oral estrogens
Soru 69Soru →

A 33-year-old woman comes to the clinic to discuss her medication regimen. She was recently diagnosed with estrogen receptor-positive breast cancer and underwent a lumpectomy with sentinel lymph node biopsy two weeks ago. Her oncologist plans to initiate adjuvant tamoxifen therapy next week. The patient has a 5-year history of major depressive disorder, which has been well controlled for the past two years with daily paroxetine. She reports that her mood is currently stable and she has no neurovegetative symptoms of depression, though she is mildly anxious about starting her new cancer treatment. She has no other medical conditions and takes no other medications. Vital signs are within normal limits. Physical examination reveals a healing surgical incision on the right breast, with no erythema or discharge. Which of the following is the most appropriate next step in the pharmacologic management of this patient's depression?

Cevabı ve açıklamayı göster

Cevap: Discontinue paroxetine and initiate venlafaxine

Cevap

Discontinue paroxetine and initiate venlafaxine
The correct course of action is to discontinue paroxetine and initiate venlafaxine. Tamoxifen is a selective estrogen receptor modulator (SERM) used as adjuvant therapy for hormone receptor-positive breast cancer. It is a prodrug that must be converted by the hepatic cytochrome P450 2D6 (CYP2D6) enzyme into its highly active metabolite, endoxifen. Paroxetine is a strong inhibitor of CYP2D6. Co-administration of paroxetine and tamoxifen prevents the formation of endoxifen, leading to reduced therapeutic efficacy and an increased rate of breast cancer recurrence. Venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI), is a weak or non-inhibitor of CYP2D6. It is considered a safe and highly effective alternative for treating depression (as well as hot flashes) in patients taking tamoxifen.

Adım Adım Çözüm

1
Identify the patient's concurrent medications and planned therapies.
The patient is currently taking paroxetine for major depressive disorder and is scheduled to begin tamoxifen for estrogen receptor-positive breast cancer.
Medication reconciliation is the critical first step to avoid adverse drug events when new therapies are introduced.
2
Evaluate potential pharmacokinetic and pharmacodynamic interactions.
Paroxetine is identified as a strong CYP2D6 inhibitor. Tamoxifen is a prodrug that requires activation by CYP2D6 into its active metabolite, endoxifen.
Concomitant use of a strong CYP2D6 inhibitor prevents the activation of tamoxifen, significantly reducing its efficacy and increasing the risk of breast cancer recurrence.
3
Determine the appropriate clinical intervention to manage the interaction.
Select an effective alternative antidepressant that does not strongly inhibit CYP2D6, such as venlafaxine.
Venlafaxine safely maintains psychiatric stability without compromising the efficacy of the patient's critical oncologic therapy.

Anahtar Kavram

Management of drug-drug interactions involving CYP2D6 inhibitors and tamoxifen

Alternatif Yöntem

While venlafaxine is an excellent choice, selective serotonin reuptake inhibitors (SSRIs) that are weak or non-inhibitors of CYP2D6, such as escitalopram or citalopram, are also safe and viable alternative options for managing depression in patients on tamoxifen.
Tahmini Süre:1m 0s
Soru 70Soru →

A 26-year-old man comes to the clinic for treatment of a painless penile chancre. Darkfield microscopy confirms the presence of Treponema pallidum, and his baseline rapid plasma reagin (RPR) titer is 1:64. He is administered a single dose of intramuscular benzathine penicillin G for primary syphilis. He is otherwise healthy, has no allergies, and tests negative for HIV. The patient asks the physician how they will know if the infection has been successfully cured. Which of the following statements represent the appropriate monitoring and evaluation plan for this patient? (Select all that apply)

Geçerli olan tümünü seçin

Cevabı ve açıklamayı göster

Cevap: Repeat non-treponemal titer testing at 6 and 12 months after treatment.; Confirmation of at least a four-fold decrease in the non-treponemal titer.

Cevap

The appropriate monitoring plan involves repeating the non-treponemal titer (RPR) at 6 and 12 months and confirming at least a four-fold decrease in the titer.
The correct answers identify that non-treponemal tests (such as RPR or VDRL) should be repeated at 6 and 12 months, and that a four-fold decrease in titer (e.g., from 1:64 to 1:16, representing two dilutions) is considered an adequate therapeutic response. Non-treponemal titers reflect current disease activity and decline gradually following successful treatment.

Adım Adım Çözüm

1
Identify the patient's diagnosis and baseline laboratory status.
The patient has primary syphilis with a baseline RPR titer of 1:64.
Establishing the baseline titer is necessary because treatment success is evaluated relative to this initial quantitative value.
2
Select the appropriate laboratory test for longitudinal monitoring.
Non-treponemal tests (RPR or VDRL) are selected over treponemal tests (TP-PA, FTA-ABS).
Non-treponemal antibody levels correlate with active disease and decline after successful treatment, whereas treponemal antibodies typically remain positive for life.
3
Determine the correct monitoring intervals and criteria for cure.
Testing should be performed at 6 and 12 months to look for at least a four-fold decrease in the RPR titer (e.g., a drop from 1:64 to 1:16 or lower).
Antibody titers decline slowly. A four-fold drop by 6 to 12 months confirms adequate treatment response, even if the titer does not become entirely negative.

Anahtar Kavram

Monitoring and Treatment Evaluation for Primary Syphilis
Soru 71Soru →

A 31-year-old man is brought to the emergency department by his partner due to severe confusion, high fever, and intractable vomiting for the past 12 hours. The partner reports that the patient was diagnosed with Graves disease two years ago but has been nonadherent to all medications for the past three months. Temperature is 40.1°C (104.2°F), pulse is 155/min, blood pressure is 162/68 mm Hg, and respirations are 26/min. Physical examination reveals a profusely diaphoretic and delirious patient. A prominent fine tremor is noted in the upper extremities. Neck examination reveals a diffusely enlarged, non-tender thyroid gland with an audible bruit. Electrocardiography demonstrates sinus tachycardia.

Arrange the following pharmacologic interventions in the strictly required chronological sequence for the acute management of this patient's condition.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct sequence is intravenous propranolol, followed by oral propylthiouracil, followed by potassium iodide solution.
The management of thyroid storm requires a strict sequence of pharmacologic interventions to prevent exacerbating the condition. Intravenous propranolol is given first to rapidly control severe sympathetic symptoms (e.g., tachycardia, hyperpyrexia, agitation) and reduce peripheral conversion of T4 to T3. Next, a thionamide such as propylthiouracil (PTU) is administered to halt the synthesis of new thyroid hormone. Finally, an iodine solution (such as potassium iodide) is given to block the release of preformed thyroid hormone (the Wolff-Chaikoff effect). The iodine must be given at least one hour after the thionamide to ensure synthesis is completely blocked; otherwise, the iodine will serve as a substrate and worsen the hyperthyroidism.

Adım Adım Çözüm

1
Administer intravenous propranolol
Rapid reduction in sympathetic overdrive and inhibition of peripheral T4 to T3 conversion
Immediate stabilization of cardiovascular status and control of adrenergic symptoms is the highest priority in thyroid storm.
2
Administer oral propylthiouracil (PTU)
Inhibition of thyroid peroxidase and blocking of new hormone synthesis
Synthesis of new thyroid hormone must be halted before exposing the hyperactive gland to a heavy iodine load.
3
Administer potassium iodide solution
Inhibition of preformed thyroid hormone release
Iodine must be given approximately 1 hour after PTU to prevent the iodine from being utilized as a substrate to produce more thyroid hormone.

Anahtar Kavram

Chronological pharmacologic sequence in the management of thyroid storm

Alternatif Yöntem

In patients with severe asthma or heart failure where non-selective beta-blockers like propranolol are contraindicated, alternative sympatholytic agents such as esmolol (cardioselective, short-acting) or diltiazem (calcium channel blocker) may be used as the first step.
Tahmini Süre:1m 0s
Soru 72Soru →

A 3838-year-old woman is evaluated in the clinic for progressive fatigue, weight gain, and cold intolerance over the past three months. Laboratory studies reveal a thyroid-stimulating hormone (TSH) level of 14.514.5 mIU/L (normal: 0.4−4.00.4-4.0 mIU/L) and a free thyroxine (T4) level of 0.60.6 ng/dL (normal: 0.9−1.70.9-1.7 ng/dL). She has no significant past medical history, takes no daily medications, and a urine pregnancy test is negative. She is diagnosed with primary hypothyroidism. Arrange the following steps in the correct chronological sequence regarding the initiation, monitoring, and evaluation of her thyroid hormone replacement therapy.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct sequence for monitoring and treatment evaluation in primary hypothyroidism begins with initiating weight-based levothyroxine, followed by checking TSH at 6 weeks, adjusting the dose as necessary, rechecking TSH 6 weeks after any adjustment, and finally transitioning to annual monitoring once a stable euthyroid state is achieved.
The management of primary hypothyroidism requires a stepwise approach to monitoring and treatment evaluation dictated by the pharmacokinetics of levothyroxine. The medication is initiated at a weight-based dose. Because it has a half-life of roughly 7 days, checking TSH before 4 to 6 weeks will yield an inaccurate assessment of the dose's efficacy. Therefore, the first TSH check is appropriately delayed to 6 weeks. If the TSH is not at goal, the dose is adjusted, which necessitates another 6-week waiting period to evaluate the new steady state. Once a patient is clinically and biochemically euthyroid on a stable dose, monitoring can safely be extended to annual intervals.

Adım Adım Çözüm

1
Initiate oral levothyroxine at a full replacement dose of approximately 1.6 mcg/kg daily.
The patient begins thyroid hormone replacement.
This is the standard starting step and dose for young, healthy adults without coronary artery disease.
2
Measure serum TSH levels 6 weeks after initiating therapy.
The initial steady-state TSH level is evaluated.
Levothyroxine has a 7-day half-life, so it takes 4-6 weeks to reach steady-state serum concentrations and accurately reflect pituitary suppression.
3
Adjust the levothyroxine dose by 12.5 to 25 mcg daily based on the initial follow-up TSH level.
The daily dose is optimized to target the normal TSH range.
If the initial TSH is not at goal, small incremental adjustments are necessary to prevent over- or under-replacement.
4
Repeat serum TSH measurement 6 weeks after the dose adjustment.
The effect of the new dose on the pituitary-thyroid axis is evaluated.
Just like the initial initiation, any dose adjustment requires another 4-6 week waiting period to reach a new steady state.
5
Transition to annual TSH monitoring once a stable, euthyroid maintenance dose is confirmed.
Long-term surveillance is established.
Once euthyroidism is achieved on a stable dose, the patient requires yearly checks to ensure the dose remains appropriate.

Anahtar Kavram

Chronological timeline for monitoring and evaluating levothyroxine replacement therapy based on medication pharmacokinetics.
Soru 73Soru →

A 7474-year-old man is evaluated on the inpatient medical ward. He was admitted 33 days ago for a severe exacerbation of chronic obstructive pulmonary disease. His home medications include warfarin for permanent atrial fibrillation and a tiotropium inhaler. On admission, he was started on intravenous methylprednisolone and oral levofloxacin. Today, he reports feeling much better with decreased dyspnea and minimal cough. His vital signs are stable, with a blood pressure of 128/76128/76 mm Hg and a heart rate of 7878/min. Routine morning laboratory results show an International Normalized Ratio (INR) of 7.27.2 (target 2.02.0-3.03.0). Physical examination reveals no petechiae, ecchymoses, or signs of gastrointestinal bleeding. Which of the following is the most appropriate next step in the management of this patient's pharmacotherapy?

Cevabı ve açıklamayı göster

Cevap: Omit the next one to two doses of warfarin, monitor the coagulation profile, and resume at a lower dose.

Cevap

The most appropriate next step is to omit the next one to two doses of warfarin, monitor the coagulation profile, and resume at a lower dose.
The correct answer involves withholding the next one to two doses of warfarin and monitoring the patient's coagulation profile. Current clinical guidelines state that for patients taking warfarin who present with an asymptomatic supratherapeutic INR between 4.54.5 and 1010, the routine use of phytonadione (Vitamin K) is not recommended. The safest and most effective approach is to hold warfarin until the INR falls back into the therapeutic range (2.02.0-3.03.0), and then resume it at a lower dose if the interacting medications (in this case, levofloxacin and methylprednisolone) are continued.

Adım Adım Çözüm

1
Analyze the patient's clinical presentation and laboratory results.
The patient has an asymptomatic supratherapeutic INR of 7.2 without any signs of active bleeding.
Determining the presence or absence of active bleeding is the critical branching point in managing warfarin-associated coagulopathy.
2
Identify the likely cause of the coagulopathy.
The recent addition of levofloxacin and methylprednisolone caused a pharmacokinetic interaction, inhibiting warfarin metabolism and altering gut flora.
Understanding the etiology helps guide future dose adjustments once the INR returns to the therapeutic range.
3
Apply evidence-based guidelines for supratherapeutic INR reversal.
For an INR between 4.5 and 10 without bleeding, guidelines recommend holding 1-2 doses of warfarin rather than administering pharmacological reversal agents.
Routine use of Vitamin K in this range provides no outcome benefit and can cause warfarin resistance, while PCC is exclusively for life-threatening hemorrhage.

Anahtar Kavram

Management of supratherapeutic INR without bleeding
Soru 74Soru →

A 42-year-old woman is evaluated in the clinic for fatigue and dyspnea on exertion. Laboratory testing reveals a microcytic anemia with a hemoglobin of 8.2 g/dL and a severely depressed serum ferritin. She is diagnosed with iron deficiency anemia secondary to heavy menstrual bleeding and is prescribed daily oral ferrous sulfate. To appropriately monitor the efficacy of her treatment, the physician considers the expected timeline of her hematologic recovery.

Arrange the following laboratory and clinical milestones in the chronological order they are expected to occur, from earliest (first) to latest (last), following the initiation of oral iron therapy.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct sequence from earliest to latest is: Peak in the peripheral blood reticulocyte count -> Noticeable elevation in the hemoglobin concentration -> Complete normalization of the hemoglobin concentration -> Normalization of serum ferritin levels.
The physiological response to oral iron therapy follows a specific chronological sequence dictated by erythropoiesis and iron storage mechanisms. The bone marrow first responds by increasing red blood cell production, leading to a reticulocytosis that peaks at 7-10 days. This is followed by a gradual increase in hemoglobin, noticeable at 2-3 weeks, which eventually normalizes by 6-8 weeks. Finally, after the functional iron compartment (hemoglobin) is restored, excess iron is deposited in tissues, normalizing ferritin levels over 3-6 months.

Adım Adım Çözüm

1
Identify the earliest sign of bone marrow response to iron supplementation.
Peak in the peripheral blood reticulocyte count.
The bone marrow immediately utilizes the newly available iron for erythropoiesis, releasing immature red blood cells (reticulocytes) into the circulation. This peaks at 7 to 10 days.
2
Determine the timeline for initial improvement in the total red cell mass.
Noticeable elevation in the hemoglobin concentration.
As reticulocytes mature and more red blood cells are continuously produced, the hemoglobin level begins to rise measurably after 2 to 3 weeks.
3
Identify when the anemia is expected to be fully resolved.
Complete normalization of the hemoglobin concentration.
It takes approximately 6 to 8 weeks for sustained red blood cell production to fully correct the hemoglobin deficit and return it to the normal reference range.
4
Determine the final goal of monitoring therapy.
Normalization of serum ferritin levels.
Once the functional iron pool (hemoglobin) is restored, the body begins storing excess absorbed iron. Normalizing ferritin to replenish stores requires continuing iron therapy for 3 to 6 months after the anemia has resolved.

Anahtar Kavram

Timeline of hematologic response and iron store repletion when evaluating treatment efficacy for iron deficiency anemia.
Tahmini Süre:1m 0s
Soru 75Soru →

A 45-year-old male patient is assessed on the surgical ward 6 days after undergoing an open reduction and internal fixation of a right femur fracture. He has been receiving prophylactic doses of subcutaneous unfractionated heparin since the operation. The patient now reports a new, deep ache in his left calf. Physical examination demonstrates unilateral left lower extremity edema with localized tenderness. A duplex ultrasonography reveals an acute, occlusive thrombus in the left popliteal vein. Laboratory testing shows a platelet count of 105,000/mm³, a significant decrease from his preoperative baseline of 260,000/mm³. His prothrombin time and activated partial thromboplastin time are within normal limits. Which of the following best describes the molecular mechanism responsible for this patient's current presentation?

Cevabı ve açıklamayı göster

Cevap: Binding of immunoglobulin G to a complex of platelet factor 4 and a therapeutic glycosaminoglycan

Cevap

Binding of immunoglobulin G to a complex of platelet factor 4 and a therapeutic glycosaminoglycan
The correct answer accurately outlines the pathophysiology of Heparin-Induced Thrombocytopenia (HIT). In HIT, the administration of a therapeutic glycosaminoglycan (heparin) leads to the formation of immunogenic complexes with endogenous platelet factor 4 (PF4). The immune system mounts an IgG antibody response against these complexes. The resulting IgG-PF4-heparin complexes bind to FcγRIIa receptors on platelet surfaces, causing robust platelet activation, aggregation, and the release of procoagulant microparticles. This cascade results in a highly thrombogenic state (manifesting as a deep vein thrombosis in this patient) and a concurrent drop in platelet count as they are consumed in the thrombi.

Adım Adım Çözüm

1
Analyze the clinical presentation and timeline.
The patient developed a >50% drop in platelets and a new venous thrombosis 6 days after starting unfractionated heparin.
Establishing the classic '4T's' criteria components (Thrombocytopenia, Timing, Thrombosis, and no other cause) points toward a specific drug-induced complication.
2
Identify the primary diagnosis.
The clinical picture is diagnostic for Heparin-Induced Thrombocytopenia (HIT) Type 2.
HIT is characterized by a paradoxical prothrombotic state combined with a consumptive thrombocytopenia following recent heparin exposure.
3
Determine the underlying pathophysiology of the diagnosis.
HIT is an immune-mediated reaction where the body forms IgG autoantibodies against a complex of endogenous Platelet Factor 4 (PF4) and exogenous heparin.
Understanding the precise molecular trigger is necessary to select the correct underlying mechanism.
4
Connect the molecular trigger to the clinical findings.
These IgG antibodies bind to the PF4-heparin complex and cross-link Fc receptors on the platelet surface, causing widespread platelet activation, subsequent thrombosis, and consumption of circulating platelets.
This fully explains both the new deep vein thrombosis and the falling platelet count seen in the patient.

Anahtar Kavram

The pathophysiology of Heparin-Induced Thrombocytopenia (HIT) Type 2 involves the formation of IgG antibodies against the heparin-Platelet Factor 4 (PF4) complex, leading to widespread platelet activation and paradoxical thrombosis.
Tahmini Süre:1m 30s
Soru 76Soru →

A 68-year-old woman is brought to the emergency department by her family due to progressive confusion, weakness, and severe constipation over the past week. She has a 40-pack-year smoking history. Her vital signs are within normal limits. Physical examination reveals lethargy and diminished deep tendon reflexes. Laboratory studies reveal:

Serum calcium: 14.1 mg/dL
Serum phosphorus: 2.1 mg/dL
Intact parathyroid hormone (PTH): 8 pg/mL (normal: 10-65 pg/mL)

A chest radiograph demonstrates a large, centrally located cavitary mass in the right lung. Which of the following best describes the underlying mechanism of this patient's electrolyte abnormality?

Cevabı ve açıklamayı göster

Cevap: Tumor secretion of a peptide homologous to parathyroid hormone

Cevap

The correct answer is the tumor secretion of a peptide homologous to parathyroid hormone, known as parathyroid hormone-related peptide (PTHrP).
This patient presents with symptomatic hypercalcemia (confusion, weakness, constipation) accompanied by hypophosphatemia and a suppressed intact parathyroid hormone (PTH) level. In the setting of a central cavitary lung mass and a heavy smoking history, the most likely diagnosis is squamous cell carcinoma of the lung. Squamous cell carcinomas classically cause humoral hypercalcemia of malignancy by secreting parathyroid hormone-related peptide (PTHrP). PTHrP shares homology with the amino-terminal end of true PTH and binds to the same receptors in the bone and kidneys. This leads to increased osteoclastic bone resorption and increased renal calcium reabsorption, resulting in hypercalcemia. It also decreases renal phosphate reabsorption, causing hypophosphatemia. The severe hypercalcemia appropriately suppresses the normal parathyroid glands, leading to a low intact PTH level on standard laboratory assays (which do not detect PTHrP).

Adım Adım Çözüm

1
Analyze the laboratory results in the context of the clinical symptoms.
The patient has severe hypercalcemia, hypophosphatemia, and an appropriately suppressed intact PTH level.
This establishes that the hypercalcemia is independent of the parathyroid gland (PTH-independent hypercalcemia).
2
Correlate the metabolic abnormality with the imaging findings and patient history.
The patient has a significant smoking history and a central cavitary lung mass, which is highly suspicious for squamous cell carcinoma of the lung.
Different histological subtypes of lung cancer are associated with specific paraneoplastic syndromes.
3
Identify the primary mechanism of hypercalcemia associated with this specific tumor type.
Squamous cell carcinoma frequently secretes PTHrP.
PTHrP binds to PTH receptors in the bone and kidney, mimicking the action of true PTH (causing hypercalcemia and hypophosphatemia) while suppressing endogenous intact PTH production.

Anahtar Kavram

Humoral hypercalcemia of malignancy is most commonly caused by the ectopic secretion of parathyroid hormone-related peptide (PTHrP), classically seen in squamous cell carcinomas (e.g., of the lung, head, and neck).
Tahmini Süre:1m 0s
Soru 77Soru →

Emergency medical services bring a 72-year-old male resident of a skilled nursing facility to the acute care setting following a two-day history of worsening confusion, fever, and purulent sputum production. Upon triage, he appears lethargic and is in mild respiratory distress. Vital signs reveal a temperature of 38.9°C (102.0°F), a blood pressure of 88/56 mmHg, a heart rate of 112/min, and a respiratory rate of 26/min. Room air pulse oximetry indicates an oxygen saturation of 89%. Auscultation of the lungs demonstrates dense, coarse crackles localized to the right lower lung base. A portable chest radiograph confirms a new dense consolidation in the right lower lobe. A review of his electronic medical record reveals a prior ischemic stroke complicated by oropharyngeal dysphagia. Notably, he was discharged from the hospital one month ago after being treated for complicated pyelonephritis with a 10-day course of intravenous levofloxacin. Blood and sputum cultures are sent to the laboratory.

Which of the following antimicrobial agents should be included in his initial empiric pharmacologic regimen? (Select all that apply)

Geçerli olan tümünü seçin

Cevabı ve açıklamayı göster

Cevap: Vancomycin; Cefepime

Cevap

Vancomycin and cefepime
The correct combination includes vancomycin and cefepime. This patient presents with severe pneumonia and has specific risk factors for resistant pathogens, namely a recent hospitalization and receipt of intravenous antibiotics within the past 90 days. Therefore, empiric therapy must be broadened beyond standard community-acquired regimens to cover Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Vancomycin provides the necessary MRSA coverage, while cefepime serves as an appropriate anti-pseudomonal beta-lactam.

Adım Adım Çözüm

1
Assess the severity of the pneumonia and identify risk factors for resistant organisms.
The patient has severe pneumonia with risk factors for MRSA and Pseudomonas aeruginosa due to a recent hospitalization and receipt of intravenous antibiotics in the last 90 days.
Identifying risk factors for resistant pathogens dictates the need to broaden empiric antimicrobial coverage beyond standard community-acquired pneumonia regimens.
2
Select appropriate empiric antimicrobial agents based on the identified risk factors.
Select an anti-MRSA agent (vancomycin) and an anti-pseudomonal beta-lactam (cefepime).
Standard community-acquired regimens are insufficient for this patient; dual coverage targeting both MRSA and Pseudomonas is required to optimize survival.

Anahtar Kavram

Patients presenting with severe pneumonia who have specific risk factors (e.g., recent hospitalization and intravenous antibiotic use within the past 90 days) require empiric broad-spectrum coverage targeting both MRSA and Pseudomonas aeruginosa.
Soru 78Soru →

A 29-year-old woman presents to the outpatient clinic for evaluation of heavy menstrual bleeding. She reports soaking through a pad every 1 to 2 hours during the first three days of her menstrual cycle. She also mentions a lifelong history of easy bruising and frequent nosebleeds that often require prolonged pressure to stop. She has no significant past medical history and takes no medications. Her vital signs are within normal limits. Laboratory evaluation reveals the following:

Hemoglobin: 11.2 g/dL11.2 \text{ g/dL}
Platelet count: 250,000/mm3250,000/\text{mm}^3
Prothrombin time (PT): 12 seconds12 \text{ seconds} (normal: 11−15 seconds11-15 \text{ seconds})
Activated partial thromboplastin time (aPTT): 45 seconds45 \text{ seconds} (normal: 25−40 seconds25-40 \text{ seconds})
Bleeding time: 12 minutes12 \text{ minutes} (normal: 2−7 minutes2-7 \text{ minutes})

Which of the following is the most likely underlying pathophysiologic mechanism for this patient's bleeding diathesis?

Cevabı ve açıklamayı göster

Cevap: Impaired synthesis or function of a carrier protein for factor VIII

Cevap

The correct underlying mechanism is the impaired synthesis or function of a carrier protein for factor VIII, which describes the pathophysiology of von Willebrand disease.
The correct answer identifies the mechanism of von Willebrand disease (vWD). Von Willebrand factor (vWF) has two critical roles in hemostasis. First, it cross-links platelet glycoproteins to exposed subendothelial collagen, thereby mediating primary hemostasis. Second, it serves as a carrier protein for factor VIII, protecting it from rapid proteolytic degradation in the circulation. A deficiency in vWF leads to impaired platelet adhesion (which prolongs the bleeding time) and a secondary decrease in circulating factor VIII (which prolongs the aPTT). The clinical presentation of mucocutaneous bleeding, such as epistaxis and menorrhagia, in a young woman with this specific laboratory profile is the classic presentation for vWD.

Adım Adım Çözüm

1
Analyze the patient's clinical presentation.
The patient has a history of easy bruising, heavy menstrual bleeding, and epistaxis, which indicates a defect in primary hemostasis (mucocutaneous bleeding).
Identifying the pattern of bleeding helps distinguish between primary hemostasis disorders (involving platelets and von Willebrand factor) and secondary hemostasis disorders (involving coagulation factors).
2
Evaluate the laboratory findings in the context of the bleeding pattern.
The patient has a normal platelet count, normal PT, prolonged aPTT, and prolonged bleeding time.
Correlating laboratory findings with the coagulation cascade points to a specific etiology.
3
Synthesize the clinical and laboratory data to identify the specific disease and its mechanism.
A prolonged bleeding time with a normal platelet count indicates a functional defect in platelet adhesion, pointing to von Willebrand disease (vWD). The accompanying prolonged aPTT confirms vWD, because von Willebrand factor acts as a carrier protein that protects factor VIII from degradation in the bloodstream.
Matching the classic laboratory profile to the underlying pathophysiology is required to select the correct mechanism.

Anahtar Kavram

von Willebrand disease (vWD) typically presents with mucocutaneous bleeding, a prolonged bleeding time (due to impaired platelet adhesion), and a prolonged aPTT (because von Willebrand factor normally protects factor VIII from rapid degradation).
Soru 79Soru →

An 72-year-old man is brought to the emergency department due to a sudden onset of rapid, irregular heartbeats and mild dizziness. His electrocardiogram confirms atrial fibrillation with a rapid ventricular response. The clinical team decides to initiate pharmacological rate control. Because the selected antiarrhythmic agent has a large volume of distribution and a long elimination half-life, the physician orders a substantial initial intravenous loading dose before transitioning to a daily oral maintenance dose. What is the primary pharmacokinetic purpose of administering the initial intravenous loading dose in this patient?

Cevabı ve açıklamayı göster

Cevap: To rapidly achieve the target therapeutic plasma concentration

Cevap

The correct answer is to rapidly achieve the target therapeutic plasma concentration.
The correct answer identifies that a loading dose is intended to rapidly achieve a target therapeutic plasma concentration. In acute settings, clinicians cannot wait the standard 4 to 5 half-lives required for a maintenance dose to reach steady state, especially when the chosen agent has a long half-life. The loading dose rapidly 'fills' the volume of distribution, immediately attaining the desired drug levels.

Adım Adım Çözüm

1
Analyze the drug's properties described in the vignette.
The drug has a large volume of distribution (VdV_d) and a long elimination half-life (t1/2t_{1/2}).
Identifying these parameters helps predict how the drug behaves when a continuous maintenance dose is started.
2
Apply the rule of steady state.
It generally takes 4 to 5 half-lives for a drug to reach its therapeutic steady-state concentration when relying strictly on a maintenance regimen.
For a drug with a long half-life, this delay is unacceptable in acute, symptomatic settings like atrial fibrillation with rapid ventricular response.
3
Determine the physiological function of the loading dose.
The loading dose calculation (Loading Dose=Cp×VdFLoading\ Dose = \frac{C_p \times V_d}{F}) provides enough immediate drug to fill the volume of distribution and instantly elevate the plasma concentration (CpC_p) to the target level.
This bridges the gap, providing immediate therapeutic effect while the maintenance dose takes over to sustain that level.

Anahtar Kavram

A loading dose is utilized to rapidly achieve a target therapeutic plasma concentration for drugs with a long half-life and large volume of distribution, bypassing the 4 to 5 half-lives typically required to reach steady state.
Tahmini Süre:1m 0s
Soru 80Soru →

A 52-year-old woman is evaluated in the hospital for progressive fatigue, shortness of breath, and visual disturbances over the past week. She underwent a deceased-donor renal transplantation 6 months ago and is currently maintained on tacrolimus, mycophenolate mofetil, and prednisone. Temperature is 38.1°C (100.6°F), pulse is 96/min, respirations are 18/min, and blood pressure is 132/78 mm Hg. Physical examination reveals crackles at both lung bases. Fundoscopy of the right eye shows extensive retinal hemorrhages and white, fluffy perivascular exudates. Laboratory studies show a leukocyte count of 2,400/mm³ and a platelet count of 90,000/mm³. The patient is started on the standard first-line intravenous antiviral therapy for her presumed infection. After 14 days, her symptoms persist, and a quantitative viral load shows progressive systemic infection. Her antiviral regimen is switched to an intravenous pyrophosphate analog, which results in a gradual clinical improvement. Which of the following molecular mechanisms most likely accounts for the failure of the initial antiviral therapy in this patient?

Cevabı ve açıklamayı göster

Cevap: Inability of the virus to catalyze the initial phosphorylation of the drug

Cevap

Inability of the virus to catalyze the initial phosphorylation of the drug
The patient's clinical presentation of fever, pneumonitis, pancytopenia, and retinitis (hemorrhages and cotton-wool spots) 6 months post-transplant is classic for severe Cytomegalovirus (CMV) infection. The standard first-line treatment is intravenous ganciclovir, a guanosine analog. To become active, ganciclovir must undergo initial phosphorylation catalyzed by the CMV-specific UL97 protein kinase, followed by subsequent phosphorylations by host cellular kinases. The active triphosphate form then competitively inhibits the viral DNA polymerase (UL54). The most common mechanism of CMV resistance to ganciclovir is a mutation in the UL97 gene, which prevents the crucial first phosphorylation step, rendering the drug inactive. The patient was successfully treated with foscarnet, a pyrophosphate analog that directly inhibits the viral DNA polymerase without requiring prior activation by viral kinases. Foscarnet's efficacy confirms that the viral DNA polymerase was still functional and susceptible, pinpointing the resistance mechanism to the initial phosphorylation step.

Adım Adım Çözüm

1
Identify the primary infectious syndrome and causative pathogen.
The patient has pneumonitis, pancytopenia, and characteristic retinitis ('pizza pie' appearance with hemorrhages and exudates) 6 months post-renal transplant. This classic presentation strongly points to tissue-invasive Cytomegalovirus (CMV).
Transplant patients on profound immunosuppression are at high risk for CMV reactivation, classically presenting with multi-organ involvement including the retina, lungs, and bone marrow.
2
Determine the first-line therapy and the salvage therapy used.
The standard first-line therapy for severe CMV is intravenous ganciclovir. The salvage therapy described as a 'pyrophosphate analog' is foscarnet.
Understanding the pharmacologic sequence is required to deduce the mechanism of resistance.
3
Deduce the mechanism of resistance to the initial drug that leaves the salvage drug effective.
Ganciclovir requires initial phosphorylation by the CMV UL97 protein kinase to become active. Foscarnet does not require phosphorylation. Therefore, a mutation in UL97 prevents ganciclovir activation but preserves foscarnet susceptibility.
Because foscarnet bypasses the initial viral phosphorylation step and directly inhibits the viral DNA polymerase (UL54), it remains effective against UL97-mutated CMV strains.

Anahtar Kavram

Cytomegalovirus (CMV) resistance to ganciclovir typically occurs via mutations in the viral UL97 protein kinase, which prevents the drug's essential initial phosphorylation step.
ÖncekiSayfa 4 / 237Sonraki
Tüm alıştırma soruları — USMLE Step 3 | Examkin